Hypermarcas (OTCMKTS:HYPMY) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Hypermarcas (OTCMKTS:HYPMY) issued its earnings results on Wednesday. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.01, Zacks reports. The firm had revenue of $473.13 million for the quarter, compared to analysts’ expectations of $450.75 million. Hypermarcas had a return on equity of 12.58% and a net margin of 20.07%.

Hypermarcas Stock Performance

Shares of Hypermarcas stock remained flat at $3.98 during trading hours on Friday. 88,527 shares of the stock were exchanged, compared to its average volume of 41,592. Hypermarcas has a one year low of $3.39 and a one year high of $5.77. The firm has a market cap of $2.80 billion, a PE ratio of 7.65 and a beta of 0.78. The company has a current ratio of 1.86, a quick ratio of 1.26 and a debt-to-equity ratio of 0.50. The business’s fifty day moving average is $4.62 and its 200 day moving average is $4.40.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group raised shares of Hypermarcas to a “strong-buy” rating in a report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Hypermarcas has a consensus rating of “Buy”.

Hypermarcas Company Profile

Hypermarcas was a Brazilian consumer-products and pharmaceutical company that later adopted the name Hypera Pharma. The company refocused its operations on pharmaceuticals after divesting a number of businesses in other consumer-goods categories. Today, Hypera Pharma develops, manufactures and markets medicines in Brazil, including prescription drugs, over-the-counter products and branded generics. Its portfolio also includes vitamins and supplements, and it sells products under brands such as Neo Química and Mantecorp.